Cream Containing Sericin and Turmeric in Psoriasis Patients

NCT06482398 | Not Yet Recruiting

• 1 other identifier: COA 0087/2024
• Study Type: interventional
• Target: 30
• Locations: 0 countries
• Sites: N/A

Brief Summary

Psoriasis lesion is divided into two parts. Half of the lesion will apply cream containing sericin and turmeric and another will apply steroid cream (control). The samples will be apply two times a day for 8 weeks. Psoriasis area and severity index, physician global assessment, body surface area of lesion, dermatology life quality index, Itching score, adverse reaction are evaluated before, after using the samples for 4 and 8 weeks.

Conditions

Psoriasis

Outcome Measures

Primary Outcomes (1)

• Psoriasis Area and Severity Index

  Physician will evaluate the psoriasis lesion using Psoriasis Area and Severity Index. The score is graded 0 to 72 (low score means less severity and high score means high severity).

  8 weeks

Secondary Outcomes (4)

• Physician Global Assessment

  8 weeks

• Body surface area of lesion

  8 weeks

• Dermatology Life Quality Index

  8 weeks

• Itching score

  8 weeks

Study Arms (2)

Sericin extract and turmeric extract cream

EXPERIMENTAL

Apply the sample 2 times a day for 8 weeks

Drug: Sericin extract and turmeric extract cream

Triamcinolone acetonide 1% cream

ACTIVE COMPARATOR

Apply the sample 2 times a day for 8 weeks

Drug: Triamcinolone acetonide 1% Cream

Interventions

Sericin extract and turmeric extract cream DRUG

Apply the sample 2 times a day for 8 weeks

Sericin extract and turmeric extract cream

Triamcinolone acetonide 1% Cream DRUG

Apply the sample 2 times a day for 8 weeks

Triamcinolone acetonide 1% cream

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Age over 18 years
• Patients with body surface area of psoriasis lesion less than 10, have psoriasis area and severity index less than 10 , and no lesion at face, hands,feet, and genital area
• No topical application on psoriasis lesion at least 2 weeks
• Willing to attend the study

You may not qualify if:

• Uncontrolled diseases
• Allergic to sericin turmeric and steroid
• Other skin diseases
• Pregnancy and lactation

Sponsors & Collaborators

• Chulalongkorn University: lead

MeSH Terms

Conditions

Psoriasis

Interventions

Sericins; Triamcinolone Acetonide

Condition Hierarchy (Ancestors)

Skin Diseases, Papulosquamous; Skin Diseases; Skin and Connective Tissue Diseases

Intervention Hierarchy (Ancestors)

Silk; Biopolymers; Polymers; Macromolecular Substances; Arthropod Proteins; Proteins; Amino Acids, Peptides, and Proteins; Triamcinolone; Pregnadienes; Pregnanes; Steroids; Fused-Ring Compounds; Polycyclic Compounds; Steroids, Fluorinated

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: QUADRUPLE
• Who Masked: PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Professor

Study Record Dates

• First Submitted: June 21, 2024
• First Posted: July 1, 2024
• Study Start: July 1, 2024
• Primary Completion: June 30, 2025
• Study Completion: July 31, 2025
• Last Updated: July 1, 2024

Record last verified: 2024-06